Measurable Residual Disease Evaluation During Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma: A Large Analysis of 1280 Patients Enrolled in TOURMALINE-MM3 and -MM4
What is the background of the study?
MRD status is the most powerful prognostic factor in NDMM and sustained MRD negativity is a surrogate for prolonged survival. Interest is growing for using MRD to guide treatment intensity and duration, particularly during maintenance. Paradoxically, MRD data in this setting is scarce and knowledge of the volatility of MRD status throughout treatment is limited.
In this video:
Dr. Bruno Paiva (Clinica Universidad de Navarra
, Pamplona, Spain) discusses MRD evaluation during Ixazomib maintenance in the TOURMALINE -MM# and -MM4 trial.
Conclusions:
This large dataset demonstrated that the prognostic value of MRD status at the start of maintenance can be enhanced by measuring MRD kinetics during treatment. Our results support the achievement and sustainability of MRD negativity as a treatment endpoint in the maintenance setting and showed poor outcomes in MRD− pts converting to MRD+, underscoring the value of serial MRD assessments to anticipate relapse and guide treatment decisions. Accordingly, ixa showed significant PFS benefit vs pbo in pts who were MRD+ at study entry and pts with persistent MRD.
_______________
Improving Lives Through Research and Patient Care
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: [ Ссылка ]
Visit our website at: [ Ссылка ]
Find us online:
Facebook: @myeloma | [ Ссылка ]
Twitter: @IMFMyeloma | [ Ссылка ]
Instagram: @imfmyeloma | [ Ссылка ]
LinkedIn: [ Ссылка ]
Support the IMF! [ Ссылка ]
Category
Nonprofits & Activism
License
Standard YouTube License
